Merz North America to Highlight Treatments at American Academy of Dermatology Annual Meeting
Merz North America announced today that Merz aesthetics products including Xeomin®, Cellfina®, Radiesse®, Ultherapy® and DeScribe® PFD Patch will be featured in oral and online ePoster presentations at the American Academy of Dermatology (AAD) annual meeting in San Diego, CA, taking place February 16-20, 2018.
“Each year, AAD provides Merz with the opportunity to connect with leaders in dermatology. This year, we are pleased to support research about our products and share valuable data from trailblazing clinicians as we advance the science of medical aesthetics,” said Terri Phillips, Vice President and Head of Global Medical Affairs. “In line with our vision to become the most admired, trusted and innovative aesthetics company, we work tirelessly to build strong and lasting relationships with dermatologists to help people live better, feel better and look better.”
- Dissolving calcium hydroxylapatite filler using sodium thiosulfate: a proof-of-concept clinical study. Deanne Mraz Robinson, MD – Connecticut Dermatology Group; Norwalk, Connecticut. [#7598, Friday, February 16, 2018: 9:15 – 9:20 am, ePoster Presentation Center 2 in Exhibit Hall]*
ePoster presentations will be available for viewing on the monitors in the Exhibit Hall from Friday, February 16 to Monday, February 19.
Multiple Merz Products
- Combined treatment of striae using calcium hydroxylapatite, ascorbic acid delivered by microneedling, and microfocused ultrasound. Gabriela Casabona, MD – Clínica Vida; São Paulo, Brazil. [#7574]*
- Improving skin laxity and the appearance of lines in the neck and décolletage using combined treatment with microfocused ultrasound and diluted calcium hydroxylapatite. Gabriela Casabona, MD – Clínica Vida; São Paulo, Brazil. [#7575]*
- Safety of incobotulinumtoxinA in the treatment of facial lines: results from a pooled analysis of randomized, prospective, controlled clinical studies. William P. Coleman, III, MD – Coleman Cosmetic Dermatologic Surgery Center; Metairie, Louisiana. [#7580]
- Efficacy of incobotulinumtoxinA for the treatment of glabellar frown lines in male subjects: post- hoc analyses from randomized, double-blind pivotal studies. Derek H. Jones, MD – Skin and Laser Physicians of Beverly Hills; Beverly Hills, California. [#7585]
- Safety and efficacy of escalating doses of incobotulinumtoxinA for extended treatment of glabellar frown lines: a randomized, double-blind study. Corey Maas, MD – The Maas Clinic; San Francisco, California. [#7651]*
- Safety and efficacy of microfocused ultrasound with visualization for the correction of moderate to severe atrophic acne scars. Corey Maas, MD – The Maas Clinic; San Francisco, California. [#7590]
- Modified technique for tissue stabilized-guided subcision for the treatment of mild-to-moderate cellulite of the buttocks and thighs. Omar Ibrahim, MD – SkinCare Physicians; Chestnut Hill, Massachusetts. [#6070]*
- Dissolving calcium hydroxylapatite filler using sodium thiosulfate: a proof-of-concept clinical study. Deanne Mraz Robinson, MD – Connecticut Dermatology Group; Norwalk, Connecticut. [#7598]*
- Sodium thiosulfate injection dissolves calcium hydroxylapatite particles: an animal study. Peter Kreymerman, MD – Merz North America, Inc.; Raleigh. [#7556]
- Pilot study examining the safety and efficacy of calcium hydroxylapatite filler with integral lidocaine to correct jawline volume loss: an update at 12 months. Margit Juhász, MD – Marmur Medical; New York. [#7134]*
- Improvement of chin profile using calcium hydroxylapatite with integral lidocaine. John Fezza, MD – Center For Sight; Sarasota, Florida. [#7489]*
DeScribe® PFD Patch
- Perfluorodecalin-infused patch in picosecond and Q-switched laser-assisted tattoo removal: assessments of optical transparency, chemical stability and safety. Jeremy Brauer, MD – The
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York. [#7605]
*Investigator-Initiated Trial supported by Merz.
XEOMIN® IMPORTANT CONSUMER SAFETY INFORMATION
Read the Medication Guide before you start receiving XEOMIN® (Zeo-min) and each time XEOMIN® is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:
- Talk to your health care provider or pharmacist
- Visit xeominaesthetic.com to obtain the FDA-approved product labeling
- Call 1-866-862-1211
Uses XEOMIN® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary).
XEOMIN® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems anytime (hours to week) after treatment with XEOMIN®:
- Problems with swallowing, speaking, or breathing. These problems can happen hours to weeks after an injection of XEOMIN® if the muscles that you use to breathe and swallow become weak after the injection. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN®.
- People with certain breathing problems may need to use muscles in their neck to help them breathe and may be at greater risk for serious breathing problems with XEOMIN®.
- Swallowing problems may last for several months. People who cannot swallow well may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving XEOMIN® have the highest risk of getting these
- Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called The symptoms of botulism include: loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing.
These problems could make it unsafe for you to drive a car or do other dangerous activities.
Do not use XEOMIN® if you are allergic to XEOMIN® or any of the ingredients in XEOMIN® (see the end of this Guide for a list of ingredients in XEOMIN®, had an allergic reaction to any other botulinum toxin products such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®, BOTOX® COSMETIC), or abobotulinumtoxinA (DISPORT®) or have a skin infection at the planned injection site.
Ask a doctor before use if you
- have a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome)
- have had any side effect from any other botulinum toxin in the past
- have a breathing problem such as asthma or emphysema
- have a history of swallowing problems or inhaling food or fluid into your lungs (aspiration)
- have bleeding problems
- have drooping eyelids
- have plans to have surgery
- have had surgery on your face
- are pregnant or plan to become pregnant. It is not known if XEOMIN® can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if XEOMIN® passes into breast XEOMIN® is not recommended for use in children younger than 18 years of age.
Tell your doctor about all of your medical conditions and all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Using XEOMIN® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received XEOMIN® in the past.
Especially tell your doctor if you
- have received any other botulinum toxin product in the last four months
- have received injections of botulinum toxin such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®, BOTOX® COSMETIC) and abobotulinumtoxinA (DISPORT®) in the past. Be sure your doctor knows exactly which product you received. The dose of XEOMIN® may be different from other botulinum toxin products that you have
- have recently received an antibiotic by injection
- take muscle relaxants
- take an allergy or cold medicine
- take a sleep medicine
- take a blood thinner medicine
Ask your doctor if you are not sure if your medicine is one that is listed above. Possible Side Effects
XEOMIN® can cause serious side effects that can be life threatening. See “Warnings.”
Headache was the most common side effect of XEOMIN® for treatment of glabellar lines. Other possible side effects include:
- dry mouth
- discomfort or pain at the injection site
- neck pain
- muscle weakness
- eye problems, including: double vision, blurred vision, drooping eyelids, swelling of your eyelids, and dry eyes. Reduced blinking can also occur. Tell your doctor or get medical help right away if you have eye pain or irritation following
XEOMIN® may cause other serious side effects including allergic reactions. Symptoms of an allergic reaction to XEOMIN® may include: itching, rash, redness, swelling, wheezing, asthma symptoms, or dizziness or feeling faint. Tell your doctor or get medical help right away if you get wheezing or asthma symptoms, or if you get dizzy or faint.
These are not all the possible side effects of XEOMIN®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
- XEOMIN® is a shot (injection) that your doctor will give
- XEOMIN® is injected into your affected
- Your doctor may change your dose of XEOMIN® until you and your doctor find the best dose for you.
General information about the safe and effective use of XEOMIN®
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XEOMIN® for a condition for which it was not prescribed. Do not give XEOMIN® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about XEOMIN® that is written for health professionals.
Active Ingredient: incobotulinumtoxinA
Inactive Ingredients: human albumin and sucrose
Copyright © 2016 Merz North America, Inc. All rights reserved.
MERZ, the MERZ logo and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KgaA.
Radiesse is a registered trademark of Merz North America, Inc. Ultherapy and Cellfina are registered trademarks of Ulthera, Inc. DeScribe is a registered trademark of ONLight Sciences, Inc. Botox, Dysport and Myobloc are registered trademarks of their respective owners.
About Merz North America, Inc.
Merz North America, Inc. is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the United States and Canada. Merz products are distributed through two divisions, Aesthetics and Neurosciences, and are developed with the goal of improving patients’ health and quality of life by delivering therapies that bring about real progress. Merz North America is a privately-held company based in Raleigh, North Carolina. To learn more about Merz North America, Inc., please visit www.merzusa.com.
With approximately 3,000 employees and 34 subsidiaries worldwide, Merz is a global leader in Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy for the treatment of movement disorders. Skincare products and a range of OTC medicines are also included in offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2016/17, the Merz Pharma Group generated revenue of EUR 1,023.2 million. More information is available at www.merz.com.
02.16.2018 [ 0 KB ]
Merz North America